James Jin

3.8k total citations · 1 hit paper
41 papers, 2.8k citations indexed

About

James Jin is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Molecular Biology. According to data from OpenAlex, James Jin has authored 41 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Cardiology and Cardiovascular Medicine, 5 papers in Internal Medicine and 3 papers in Molecular Biology. Recurrent topics in James Jin's work include Atrial Fibrillation Management and Outcomes (27 papers), Cardiac Arrhythmias and Treatments (21 papers) and Cardiac electrophysiology and arrhythmias (13 papers). James Jin is often cited by papers focused on Atrial Fibrillation Management and Outcomes (27 papers), Cardiac Arrhythmias and Treatments (21 papers) and Cardiac electrophysiology and arrhythmias (13 papers). James Jin collaborates with scholars based in United States, Germany and Spain. James Jin's co-authors include Bhupendra Khatri, Frederik Barkhof, Tracy Stites, Ludwig Kappos, Jean Pelletier, Hans‐Peter Hartung, Klaus Tiel‐Wilck, Gıancarlo Comı, Jeffrey A. Cohen and Ruggero Capra and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

James Jin

37 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

2010 1.6k citations Jeffrey A. Cohen, Frederik Barkhof et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Jin United States	12	1.2k	1.0k	815	427	350	41	2.8k
Richard Brandl Germany	24	108 0.1×	531 0.5×	891 1.1×	98 0.2×	175 0.5×	61	2.5k
Kelly A. Volcik United States	27	264 0.2×	703 0.7×	601 0.7×	35 0.1×	175 0.5×	48	2.8k
Zhengyu Luo United States	13	153 0.1×	398 0.4×	985 1.2×	115 0.3×	148 0.4×	22	2.1k
Enrico Floßmann United Kingdom	14	77 0.1×	419 0.4×	230 0.3×	349 0.8×	247 0.7×	23	1.8k
Barbara Girerd France	33	112 0.1×	1.4k 1.3×	757 0.9×	37 0.1×	151 0.4×	68	3.9k
Cuong V. Nguyen United States	21	489 0.4×	397 0.4×	656 0.8×	88 0.2×	591 1.7×	73	2.1k
Götz Münch Germany	26	141 0.1×	1.2k 1.2×	686 0.8×	28 0.1×	169 0.5×	66	2.2k
Roger Kranzhöfer Germany	15	118 0.1×	681 0.7×	418 0.5×	31 0.1×	177 0.5×	23	1.9k
Hidekazu Ota Japan	18	413 0.3×	186 0.2×	277 0.3×	54 0.1×	407 1.2×	74	1.3k
Shailender Singh United States	21	216 0.2×	356 0.3×	240 0.3×	68 0.2×	558 1.6×	102	1.8k

Countries citing papers authored by James Jin

Since Specialization

Citations

This map shows the geographic impact of James Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Jin more than expected).

Fields of papers citing papers by James Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Jin. The network helps show where James Jin may publish in the future.

Co-authorship network of co-authors of James Jin

This figure shows the co-authorship network connecting the top 25 collaborators of James Jin. A scholar is included among the top collaborators of James Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Jin. James Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hengstenberg, Christian, Martin Unverdorben, Helge Möllmann, et al.. (2024). Risk Factors of Ischemic Stroke in Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation from the Randomized ENVISAGE-TAVI AF Trial. The American Journal of Cardiology. 227. 98–104. 1 indexed citations

Zahir, Hamim, et al.. (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study. Clinical Pharmacology & Therapeutics. 116(3). 736–746. 1 indexed citations

Chen, Cathy, Manish Saxena, Christian von Heymann, et al.. (2023). Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database. BDJ Open. 9(1). 38–38.

Zhou, Xiaofei, et al.. (2023). 17 Humanized NKP46 mouse models for testing novel NK cell-based immunotherapies. SHILAP Revista de lepidopterología. A19–A19. 1 indexed citations

Yamamoto, Masanori, Kentaro Hayashida, Christian Hengstenberg, et al.. (2023). Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial Fibrillation. The American Journal of Cardiology. 207. 150–158. 1 indexed citations

Zhou, Xiaofei, et al.. (2023). Abstract 5178: Humanized OX40/OX40L mice as a tool for evaluating novel therapeutics. Cancer Research. 83(7_Supplement). 5178–5178.

Hengstenberg, Christian, Nicolas M. Van Mieghem, Xiaomei Ye, et al.. (2023). Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial. The American Journal of Cardiology. 209. 212–219. 1 indexed citations

Mehran, Roxana, Alessandro Spirito, James Jin, et al.. (2023). Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVR. JACC Advances. 2(2). 100259–100259.

Jin, James, Árpád Szomor, Florian Hiemeyer, et al.. (2021). 826O Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial. Annals of Oncology. 32. S773–S774. 2 indexed citations

10.

Unverdorben, Martin, Christian von Heymann, Amparo Santamaría, et al.. (2020). Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study. BMC Cardiovascular Disorders. 20(1). 504–504. 2 indexed citations

11.

Goette, Andreas, Gregory Y.H. Lip, James Jin, et al.. (2020). Differences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study). The American Journal of Cardiology. 131. 27–32. 10 indexed citations

12.

Lip, Gregory Y.H., José Luís Merino, Maciej Banach, et al.. (2018). Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). The American Journal of Cardiology. 123(4). 592–597. 10 indexed citations

13.

Fanola, Christina, Christian T. Ruff, Sabina A. Murphy, et al.. (2017). EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF – TIMI 48 RANDOMIZED CLINICAL TRIAL. Journal of the American College of Cardiology. 69(11). 325–325. 6 indexed citations

14.

Lip, Gregory Y.H., José Luís Merino, Gheorghe‐Andrei Dan, et al.. (2017). Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study). The American Journal of Cardiology. 121(2). 193–198. 5 indexed citations

15.

Goette, Andreas, José Luís Merino, Michael D. Ezekowitz, et al.. (2016). Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. The Lancet. 388(10055). 1995–2003. 177 indexed citations

16.

Lip, Gregory Y.H., José Luís Merino, Michael D. Ezekowitz, et al.. (2015). A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American Heart Journal. 169(5). 597–604.e5. 29 indexed citations

17.

Han, Kelong, Min Ren, Wolfgang Wick, et al.. (2013). Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro-Oncology. 16(5). 696–706. 106 indexed citations

18.

Cohen, Jeffrey A., Frederik Barkhof, Gıancarlo Comı, et al.. (2010). Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine. 362(5). 402–415. 1638 indexed citations breakdown →

19.

Puig, Juan, et al.. (2009). Evaluation of the dose—response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics. 31(12). 2839–2850. 10 indexed citations

20.

Philipp, Thomas, Timothy R. Smith, Robert Glazer, et al.. (2007). Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clinical Therapeutics. 29(4). 563–580. 212 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact